Author

N. S. Callander

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:flow cytometry· 1 Assay:proteomics· 1

Frequent Co-Authors

E. Flietner· 2 shared F. Asimakopoulos· 2 shared P. Hematti· 2 shared A. Hudson· 1 shared A. M. Cunningham· 1 shared A. Pagenkopf· 1 shared A. Papadas· 1 shared A. Rajagopalan· 1 shared

Activity by Year

2018-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. Flietner

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Genomic and transcriptional profiling stratifies VQ myeloma lines into two clusters with distinct risk signatures and drug responses

E. Flietner, M. Yu, A. Rajagopalan, Y. Zhou, Y. Feng, A. Veltri, T. Lasho, Z. Wen, Y. Sun, M. M. Patnaik, N. S. Callander, F. Asimakopoulos, D. Wang, J. Zhang

bioRxiv · Aug 21, 2022 · PreprintCancer Biology

Inflammatory CD4/CD8 double positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology

N. J. Hess, D. P. Turicek, J. Riendeau, S. J. McIlwain, E. Contreras Guzman, K. Nadiminti, A. Hudson, N. S. Callander, M. C. Skala, J. E. Gumperz, P. Hematti, C. M. Capitini

This study identifies CD4+/CD8+ double positive T cells as mediators of xenogeneic GVHD but with limited GVL activity.

bioRxiv · Jan 11, 2022Immunology

Versican Proteolysis Predicts Immune Effector Infiltration And Post-Transplant Survival In Myeloma

B. Dhakal, A. Pagenkopf, M. U. Mushtaq, A. M. Cunningham, E. Flietner, Z. Morrow, A. Papadas, C. Hope, C. Leith, P. Hematti, P. Hari, N. S. Callander, F. Asimakopoulos

This study shows that VCAN proteolysis predicts CD8+ T cell infiltration and poor survival after myeloma transplantation, suggesting it as a biomarker for relapse risk.

bioRxiv · Sep 12, 2018Immunology